Johannes Hoffmann (vascular surgeon)

M&L Healthcare's First MedTech Investment Receives FDA Approval Following Successful US Trials

Retrieved on: 
Monday, September 18, 2023

The approval comes after successful outcomes in the PROMISE II Pivotal trial in the United States, recently published in the New England Journal of Medicine.

Key Points: 
  • The approval comes after successful outcomes in the PROMISE II Pivotal trial in the United States, recently published in the New England Journal of Medicine.
  • It is the first and only FDA-approved device for TADV and provides no-option CLTI patients with access to a minimally invasive treatment.
  • Type 2 diabetes is a major cause of CLTI, a condition that affects millions of people globally.
  • The United States alone witnesses approximately 150,000 ischemic amputations each year, resulting in healthcare costs of over US$95 billion.

NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF JOSHUA DETILLIO AS ITS NEW CHIEF OPERATING OFFICER

Retrieved on: 
Tuesday, September 5, 2023

HOUSTON, Sept. 5, 2023 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Joshua DeTillio as the Company's Chief Operating Officer effective on or about October 2, 2023.

Key Points: 
  • HOUSTON, Sept. 5, 2023 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Joshua DeTillio as the Company's Chief Operating Officer effective on or about October 2, 2023.
  • Mr. DeTillio is an experienced healthcare leader with over 20 years of hospital experience and 12 years as a CEO in investor-owned, publicly traded companies.
  • I'm looking forward to being a part of the journey and to add value along the way," stated Josh DeTillio, FACHE, MBA, Chief Operating Officer of Nutex Health.
  • We look forward to working with him on driving efficient and profitable growth for many years to come," stated Warren Hosseinion, M.D., President of Nutex Health.

Global Thought Leaders Continue to Join the VESTECK Advisory Team

Retrieved on: 
Thursday, January 5, 2023

WEST CHESTER, Pa., Jan. 5, 2023 /PRNewswire/ -- VESTECK, Inc. is proud to announce that another global Endovascular thought leader, Professor Michel Reijnen has agreed to join the VESTECK Scientific Advisory Board.

Key Points: 
  • WEST CHESTER, Pa., Jan. 5, 2023 /PRNewswire/ -- VESTECK, Inc. is proud to announce that another global Endovascular thought leader, Professor Michel Reijnen has agreed to join the VESTECK Scientific Advisory Board.
  • The VESTECK "SUTURE-TIGHT"™ catheter secures endovascular aortic repair grafts (EVAR) to the aorta at the time of initial implant or during repair procedures.
  • VESTECK CEO, Joe Rafferty commented, "we are honored to have Professor Reijnen join our Scientific Advisory Board.
  • On the VESTECK Scientific Advisory Board, Professor Reijnen joins global thought leaders: Sean Lyden MD Cleveland Clinic, Daniel Clair MD Vanderbilt Univ., Prof. Andrew Holden Auckland Hosp NZ, William Gray MD Main Line Health, Dai Yamanouchi MD Univ.

Melissa D. Shah, MD is recognized by Continental Who's Who

Retrieved on: 
Monday, August 15, 2022

ALBANY, N.Y., Aug. 15, 2022 /PRNewswire/ -- Melissa D. Shah, MD, is being recognized by Continental Who's Who as a Trusted Healthcare Professional for her outstanding work as a Vascular Surgeon and in acknowledgment of her excellence at Albany Med Vascular Group.

Key Points: 
  • ALBANY, N.Y., Aug. 15, 2022 /PRNewswire/ -- Melissa D. Shah, MD, is being recognized by Continental Who's Who as a Trusted Healthcare Professional for her outstanding work as a Vascular Surgeon and in acknowledgment of her excellence at Albany Med Vascular Group.
  • A highly trained expert in her field, Dr. Shah has practiced at Albany Med Vascular Group for over 20 years.
  • Co-founded by Dr. Shah's father, the medical clinic is the largest provider of vascular surgery in the northeastern United States.
  • Today, many procedures pioneered by the Albany Med Vascular Group team are considered standard of care.

VESTECK, Inc. Delivers multiple presentations at Charring Cross International Symposium

Retrieved on: 
Wednesday, May 11, 2022

WEST CHESTER, Pa., May 11, 2022 /PRNewswire/ -- VESTECK, Inc. is pleased to announce their participation and strong podium presence at the Charring Cross International Vascular Symposium.

Key Points: 
  • WEST CHESTER, Pa., May 11, 2022 /PRNewswire/ -- VESTECK, Inc. is pleased to announce their participation and strong podium presence at the Charring Cross International Vascular Symposium.
  • "Charring Cross" (CX), held annually in London, UK, is considered one of the premier global Vascular/Endovascular symposiums.
  • Key Opinion Leaders from around the world assemble to candidly discuss the most recent breakthroughs and controversies.
  • CX attendees spent an entire day discussing solutions to the current challenges with the durability of endovascular aortic repair grafts (EVAR/TEVAR).

VESTECK, Inc. Expands Scientific Advisory Board

Retrieved on: 
Friday, May 6, 2022

WEST CHESTER, Pa., May 6, 2022 /PRNewswire/ -- VESTECK, Inc. is pleased to announce the expansion of their Scientific Advisory Board with the addition of Dr. Dai Yamanouchi.

Key Points: 
  • WEST CHESTER, Pa., May 6, 2022 /PRNewswire/ -- VESTECK, Inc. is pleased to announce the expansion of their Scientific Advisory Board with the addition of Dr. Dai Yamanouchi.
  • Dr. Yamanouchi joins a world class VESTECK SAB team that includes endovascular luminaries like:
    Dr. Daniel Clair, the Chair of the Department of Vascular Surgery at Vanderbilt Univ.
  • The VESTECK Suture-Tight catheter secures endovascular grafts to the aorta at the time of initial implant or during repair procedures.
  • VESTECK is by Kevin M. Granahan of Fox Rothschild LLP
    View original content to download multimedia: https://www.prnewswire.com/news-releases/vesteck-inc-expands-scientific-...